View Older Stories View More Recent Stories

Jan 25, 2021 07:30AM Arrowhead Pharmaceuticals Files IND for Phase 2b Study of ARO-ANG3 for Treatment of Mixed Dyslipidemia
Jan 19, 2021 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2021 First Quarter Results
Dec 7, 2020 04:10PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Nov 30, 2020 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
Nov 25, 2020 07:30AM Arrowhead Pharmaceuticals Announces Closing of Agreement with Takeda
Nov 23, 2020 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2020 Year End Results
Nov 13, 2020 10:00AM Arrowhead Presents New Clinical Data on Cardiometabolic Pipeline at AHA 2020
Nov 13, 2020 09:02AM Arrowhead Pharmaceuticals Inc. (ARWR) Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease
Nov 13, 2020 09:00AM Arrowhead Interim Clinical Data Demonstrate ARO-AAT Treatment Improved Multiple Biomarkers of Alpha-1 Liver Disease
Nov 9, 2020 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming Conferences
Nov 4, 2020 07:30AM Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinars on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
Nov 2, 2020 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Year End Results
Oct 8, 2020 07:32AM Takeda (TAK) and Arrowhead (ARWR) Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Oct 8, 2020 07:30AM Takeda and Arrowhead Collaborate to Co-Develop and Co-Commercialize ARO-AAT for Alpha-1 Antitrypsin-Associated Liver Disease
Sep 30, 2020 04:01PM Arrowhead Pharmaceuticals to Participate in Upcoming Investor Conference
Sep 24, 2020 04:30PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Sep 16, 2020 07:32AM Arrowhead (ARWR) ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment
Sep 16, 2020 07:30AM Arrowhead ARO-AAT Phase 2 Interim Results in Patients with Alpha-1 Liver Disease Demonstrate Improvements in Key Parameters after Six Months of Treatment
Sep 8, 2020 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming September 2020 Conferences
Sep 8, 2020 07:30AM Arrowhead Pharmaceuticals Appoints Oye Olukotun to Board of Directors
Aug 31, 2020 05:50AM Arrowhead Pharmaceuticals Inc. (ARWR) Highlights Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
Aug 31, 2020 04:50AM Arrowhead Presents Positive New Phase 1/2 Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3 at European Society of Cardiology Congress 2020
Aug 28, 2020 07:33AM Arrowhead (ARWR), Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress
Aug 28, 2020 07:30AM Arrowhead and Collaborator Janssen Present Phase 2 Clinical Data on Investigational Hepatitis B Therapeutic JNJ-3989 at The Digital Liver Congress
Aug 18, 2020 08:00AM Arrowhead Pharmaceuticals to Participate in Upcoming August 2020 Conferences
Aug 18, 2020 07:32AM Arrowhead Pharmaceuticals Inc. (ARWR) Begins Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Aug 18, 2020 07:30AM Arrowhead Pharmaceuticals Initiates Phase 1b Study of ARO-HIF2 for Treatment of Clear Cell Renal Cell Carcinoma
Aug 11, 2020 07:34AM Arrowhead Pharmaceuticals Inc. (ARWR) Begins First Subject Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis
Aug 11, 2020 07:30AM Arrowhead Pharmaceuticals Initiates Dosing Phase 1/2 Study of ARO-ENaC for Treatment of Cystic Fibrosis
Aug 5, 2020 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2020 Third Quarter Results
Jul 29, 2020 07:36AM Arrowhead Pharmaceuticals (ARWR) Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890
Jul 29, 2020 07:30AM Arrowhead Pharmaceuticals Earns $20 Million Milestone Payment from Amgen for Start of Phase 2 Trial of AMG 890
Jul 28, 2020 11:59AM Arrowhead Pharmaceuticals Hosts Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
Jul 24, 2020 04:10PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Jul 9, 2020 07:30AM Arrowhead Pharmaceuticals to Host Key Opinion Leader Webinar on ARO-ENaC for Treatment of Cystic Fibrosis
Jul 8, 2020 04:00PM Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Third Quarter Results
May 28, 2020 07:30AM Arrowhead Pharmaceuticals to Participate in Upcoming June 2020 Conferences
May 7, 2020 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2020 Second Quarter Results
May 1, 2020 04:00PM Arrowhead Pharmaceuticals Inc. (ARWR) Announces Retirement of COO Bruce Given
May 1, 2020 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming May 2020 Conferences
May 1, 2020 04:00PM Arrowhead Pharmaceuticals Announces Retirement of COO Bruce Given
Apr 22, 2020 07:30AM Arrowhead Pharmaceuticals to Webcast Fiscal 2020 Second Quarter Results
Apr 13, 2020 06:02AM Arrowhead Pharmaceuticals Inc. (ARWR) Reports Regulatory Clearance to Begin Phase 1/2a Study of ARO-ENaC for Treatment of CF
Apr 10, 2020 07:30AM Arrowhead Pharmaceuticals Files for Regulatory Clearance to Begin Phase 1/2a Study of ARO-ENaC for Treatment of Cystic Fibrosis
Mar 17, 2020 04:10PM Arrowhead Pharmaceuticals Announces Precautionary Measures to Mitigate Effects of Novel Coronavirus (COVID-19) Spread
Mar 17, 2020 04:10PM Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Marketplace Rule 5635(c)(4)
Mar 3, 2020 07:30AM Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-HSD in Normal Healthy Volunteers and Patients with NASH or Suspected NASH
Mar 2, 2020 04:00PM Arrowhead Pharmaceuticals to Participate in Upcoming March 2020 Conferences
Feb 5, 2020 04:00PM Arrowhead Reports Interim Clinical Data on Cardiometabolic Candidates ARO-APOC3 and ARO-ANG3
Feb 5, 2020 04:00PM Arrowhead Pharmaceuticals Reports Fiscal 2020 First Quarter Results
View More Recent Stories View Older Stories